Related Experiment Video

Updated: Jun 18, 2026

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Platelet hyper-reactivity in active inflammatory arthritis is unique to the adenosine diphosphate pathway: a novel

Paul A Mac Mullan1, Aaron J Peace, Anne M Madigan

  • 1Department of Rheumatology, Mater Misericordiae University Hospital, RCSI, Dublin, Ireland.

Rheumatology (Oxford, England)
|December 8, 2009
PubMed

Insights

Patients with active inflammatory arthritis (IA) show increased platelet reactivity, specifically via the adenosine diphosphate (ADP) pathway. This heightened platelet response may contribute to their elevated cardiovascular risk.

Area of Science:

  • Rheumatology
  • Cardiovascular Medicine
  • Hematology

Background:

  • Inflammatory arthritis (IA) is associated with increased cardiovascular disease (CVD) risk.
  • Platelet activation and function may play a role in the pro-thrombotic state observed in IA.
  • Understanding the specific mechanisms of platelet dysfunction in IA is crucial for risk stratification and management.

Purpose of the Study:

  • To investigate the impact of active disease on platelet function in patients with inflammatory arthritis (IA).
  • To compare platelet reactivity in patients with active IA versus those with controlled disease.
  • To identify specific pathways of platelet activation influenced by disease activity.

Main Methods:

  • Ninety-six patients with IA (RA, PsA, seronegative SpA) were enrolled, excluding those with CVD, diabetes, or on anti-platelet therapy.
  • Patients were categorized into active disease (n=38) or control disease (n=58) based on validated disease activity measures.
  • Platelet function was assessed using light transmission aggregometry, measuring aggregation in response to various agonists, including adenosine diphosphate (ADP).

Main Results:

  • Demographics and CVD risk factors were comparable between active and control groups.
  • Platelet aggregation in response to adenosine diphosphate (ADP) was significantly increased in patients with active IA compared to controls (P < 0.001).
  • No significant differences in platelet reactivity were observed for other agonists tested.

Conclusions:

  • Active inflammatory arthritis is associated with enhanced platelet reactivity, specifically through the ADP-dependent pathway.
  • This augmented platelet response in active IA may represent a pro-thrombotic tendency.
  • The findings suggest a potential mechanism contributing to the increased cardiovascular risk in patients with active inflammatory arthritis.
Abstract

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...